QUINTESSENTIAL
A Phase 2, Open-Label, Multicenter Study of BMS-986363, a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 150 patients (estimated)
- Sponsors
- Celgene Corporation, a wholly owned subsidiary of Bristol Myers Squibb, Juno Therapeutics, a Bristol-Myers Squibb Company
- Collaborators
- Juno Therapeutics, a Bristol-Myers Squibb Company
- Tags
- CAR T Cell, GPRC5D
- Trial Type
- Treatment
- Last Update
- 1 day ago
- SparkCures ID
- 1843
- NCT Identifier
- NCT06297226
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.